The European Medicines Agency's approval of new medicines for type 2 diabetes
Author:
Affiliation:
1. European Medicines Agency; London UK
2. Medical Products Agency; Uppsala Sweden
3. Dutch Medicines Evaluation Board; Utrecht The Netherlands
Publisher
Wiley
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.13349/fullpdf
Reference31 articles.
1. Health at a Glance: Europe 2016
2. Effects of Sotagliflozin added to insulin in patients with type 1 diabetes;Garg;N Engl J Med,2017
3. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of diabetes;Inzucchi;Diabetologia,2015
4. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of diabetes;Nathan;Diabetologia,2006
5. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas;Deacon;Diabetes Obes Metab,2016
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options;Frontiers in Cardiovascular Medicine;2023-07-27
2. Adherence to the therapeutic guidelines recommendations among the people with type 2 diabetes mellitus and obesity, frailty, or recent diagnosis, attended in primary health care centers in Spain: A cross-sectional study;Frontiers in Medicine;2023-03-24
3. Longitudinal deep learning clustering of Type 2 Diabetes Mellitus trajectories using routinely collected health records;Journal of Biomedical Informatics;2022-11
4. Evaluation of Insulin and Glucagon-Like Peptide-1 Analog Sales in Turkey Before the Pandemic Period; Projection for Upcoming Years: A Market Analysis Study;Sakarya Medical Journal;2022-10-07
5. Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies;Advances in Therapy;2021-09-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3